Table 1.
Characteristics of assessed patients.
| Variable | N = 476 |
|---|---|
| Cancer type | |
| Epithelial ovarian cancer | 386 (81%) |
| Fallopian tube cancer | 43 (9%) |
| Primary peritoneal cancer | 47 (10%) |
| Histological classification | |
| Serous | 449 (94%) |
| Others | 27 (6%) |
| Platinum-sensitivity of the recurrent disease | |
| Sensitive | 299 (63%) |
| Resistant | 138 (29%) |
| Refractory | 39 (8%) |
| BRCA mutational status | |
| BRCA1 | 117 (25%) |
| BRCA2 | 57 (12%) |
| BRCA wild-type | 302 (63%) |
| Homologous recombination deficiency (HRD) status | |
| BRCA1 mutation | 117 (25%) |
| BRCA2 mutation | 57 (12%) |
| BRCA, wild type LOH-high | 126 (26%) |
| BRCA, wild type LOH-low | 152 (32%) |
| BRCA, wild type LOH(unknown) | 24 (5%) |
| Best radiological response after 100 days according to RECIST criteria | |
| Complete response | 23 (5%) |
| Partial response | 125 (26%) |
| Stable disease | 141 (30%) |
| Progressive disease | 63 (13%) |
| Not evaluable | 124 (26%) |
| CA-125 response according to the GCIG | |
| Unfavorable | 175 (37%) |
| Favorable | 107 (22%) |
| Not evaluablea | 194 (41%) |
| Key outcome measures | |
| Platinum-sensitive cohort (n = 299) | |
| Best subsequent radiological response | |
| Complete response | 21 (7%) |
| Partial response | 96 (32%) |
| Stable disease | 92 (31%) |
| Progressive disease | 37 (12%) |
| Not evaluable | 53 (18%) |
| Progression-free survival (PFS) with a 100 day landmark | 5.3 [4.1–6.00] |
| Platinum-resistant cohort (n = 177) | |
| Best subsequent radiological response | |
| Complete response | 2 (1%) |
| Partial response | 29 (16%) |
| Stable disease | 49 (28%) |
| Progressive disease | 26 (15%) |
| Not evaluable | 71 (40%) |
| Progression-free survival (PFS) with a 100 day landmark | 4.1 [4.0–5.5] |
LOH: loss-of-heterozygosity.
a
CA-125 response according to the GCIG: baseline CA-125 not available or baseline <2 N (70 kU/L).